Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
VIEWORKS
TeraRecon

Identifying Brain Networks Using Metabolic Brain Imaging-Based Mapping Strategy

By Medimaging International staff writers
Posted on 31 Jul 2014
Image: PET scans highlight the loss of dopamine storage capacity in Parkinson’s disease. In the scan of a disease-free brain, made with [18F]-FDOPA PET (left image), the red and yellow areas show the dopamine concentration in a normal putamen, a part of the mid-brain. Compared with that scan, a similar scan of a Parkinson’s patient (right image) shows a marked dopamine deficiency in the putamen (Photo courtesy of the Feinstein Institute’s Center for Neurosciences).
Image: PET scans highlight the loss of dopamine storage capacity in Parkinson’s disease. In the scan of a disease-free brain, made with [18F]-FDOPA PET (left image), the red and yellow areas show the dopamine concentration in a normal putamen, a part of the mid-brain. Compared with that scan, a similar scan of a Parkinson’s patient (right image) shows a marked dopamine deficiency in the putamen (Photo courtesy of the Feinstein Institute’s Center for Neurosciences).
A new image-based strategy has been used to identify and gauge placebo effects in randomized clinical trials for brain disorders. The researchers employed a network mapping technique to identify specific brain circuits underlying the response to sham surgery in Parkinson’s disease (PD).

The study’s findings were published in the July 18, 2014, in the Journal of Clinical Investigation. PD is the second most common neurodegenerative disease in the United States. Those who suffer from Parkinson’s disease most frequently experience tremors, slowness of movement (bradykinesia), rigidity, and impaired balance and coordination. Patients may have a hard time talking, walking, or completing simple daily tasks. They may also experience depression and difficulty sleeping due to the disease. The current standard for diagnosis of PD disease relies on a skilled healthcare professional, typically an experienced neurologist, to determine through clinical examination that someone has it. Currently, there is no cure for PD, but drugs can improve symptoms.

Investigators from the Feinstein Institute’s Center for Neurosciences (Manhasset, NY, USA), led by David Eidelberg, MD, has developed a strategy to identify brain patterns that are abnormal or indicate disease using 18-F flurorodeoxyglucose (FDG) positron emission tomography (PET) metabolic imaging techniques. Up to now, this approach has been used effectively to identify specific networks in the brain that indicate a patient has or is at risk for PD and other neurodegenerative disorders.

“One of the major challenges in developing new treatments for neurodegenerative disorders such as Parkinson’s disease is that it is common for patients participating in clinical trials to experience a placebo or sham effect,” noted Dr. Eidelberg. “When patients involved in a clinical trial commonly experience benefits from placebo, it’s difficult for researchers to identify if the treatment being studied is effective. In a new study conducted by my colleagues and myself, we have used a new image-based strategy to identify and measure placebo effects in brain disorder clinical trials.”

The researchers used their network mapping technique in this study to identify specific brain circuits underlying the response to sham surgery in PD patients participating in a gene therapy trial. The expression of this network measured under blinded conditions correlated with the sham study participants’ clinical outcome; the network changes were reversed when the subjects learned of their sham treatment status.

Lastly, an individual’s network expression value measured before the treatment predicted his/her subsequent blinded response to sham treatment. This suggests, according to the investigators, that this innovative image-based measure of the sham-related network can help to reduce the number of subjects assigned to sham treatment in randomized clinical trials for brain disorders by excluding those patients who are more liable to display placebo effects under blinded conditions.

Related Links:

Feinstein Institute’s Center for Neurosciences



Channels

Radiography

view channel

Coronary CT Used to Measure a Recreational Athlete's Risk of a Cardiovascular Event

Researchers presented the results of the Measuring Athlete's Risk of Cardiovascular events (MARC) study at the 2015 European Congress of Radiology (ECR) in Vienna (Austria).  Researchers at the University Medical Center Utrecht (UMC; Utrecht, Netherlands) investigated the added value of low-dose ECG-triggered Coronary... Read more

MRI

view channel

Bayer Shows its Latest Development in MR Injectors

The latest contrast delivery and management innovation from Bayer HealthCare takes the form of the Medrad MRXperion magnetic resonance Injection System, launched at the European Congress of Radiology 2015 in Vienna (Austria). Bayer (Leverkusen, Germany) has begun to introduce the product in select countries with commercial... Read more

Ultrasound

view channel

Breakthrough Ultrasound Treatment for Alzheimer's Developed

A new, revolutionary technique that can be used to treat Alzheimer's disease and restore memory has been discovered by researchers at the University of Queensland (Queensland, Australia). The treatment uses noninvasive ultrasound to break apart neurotoxic amyloid plaques that cause cognitive decline and memory loss,... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

New Release of Image Management and Advanced Visualization Solution Unveiled at ECR 2015

A new version of an enterprise medical image management and advanced visualization solution has been launched at the 2015 European Congress of Radiology (ECR) in Vienna (Austria). The visualization solution provider also released new processing capabilities for cardiac Magnetic Resonance (MR), optimized low-dose workflow... Read more

Industry News

view channel

Analysis of Worldwide CT Scanner Sector Released

A report by Kalorama Information (New York, NY, USA) analyzing the global Computed Tomography (CT) market has been published. The report surveyed the CT market outlook until 2018, and the drivers behind the changes. The report investigated CT market sizing, market forecast to 2018, analysis of trends, how the market... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.